Bristol Myers Squibb rose 33.8% in a year. Merck rose 62.3%.

Same industry

BMY against four drug peers, a year at 100

BMY is up 33.8% in a year. Merck is up 62.3% and Eli Lilly 37.2%. Of these four, Johnson & Johnson (+32.6%) and AbbVie (+15.3%) did less. Weekly closes, Oct 10, 2025 = 100, on a log scale, so the same percentage move is the same height on every line.

Share this chart

BMY +33.8%. Merck +62.3%, Eli Lilly +37.2%, Johnson & Johnson +32.6%, AbbVie +15.3%. Weekly closes, Oct 10, 2025 = 100, log scale.

Share this chart

End-of-day closes (Databento EOD), the last close of each week. The four peers are the largest US-listed companies by market value in BMY’s SEC industry (Pharmaceutical Preparations) with a year of closes. It shows what the closes did; a move here is not a cause, a forecast or a call.

BMY: stories, the record and filings →